Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 16/20 | 0.89 |
| ▸ | KDM4E | B2RXH2 | 13/20 | 0.89 |
| ▸ | MAPT | P10636 | 13/20 | 0.89 |
| ▸ | SMN1; SMN2 | Q16637 | 12/20 | 0.89 |
| ▸ | ALDH1A1 | P00352 | 12/20 | 0.89 |
| ▸ | HPGD | P15428 | 9/20 | 0.89 |
| ▸ | HSD17B10 | Q99714 | 7/20 | 0.89 |
| ▸ | GAA | P10253 | 3/20 | 0.89 |
| ▸ | CASP3 | P42574 | 3/20 | 0.89 |
| ▸ | SENP7 | Q9BQF6 | 3/20 | 0.89 |
| ▸ | SENP6 | Q9GZR1 | 3/20 | 0.89 |
| ▸ | SENP8 | Q96LD8 | 2/20 | 0.89 |
| ▸ | NPC1 | O15118 | 15/20 | 0.74 |
| ▸ | TP53 | P04637 | 8/20 | 0.68 |
| ▸ | TSHR | P16473 | 1/20 | 0.68 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.62 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.62 |
| ▸ | RELA | Q04206 | 2/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.62 |
| ▸ | AGPAT2 | O15120 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12643346 | 0.88 | RAB9A (0.89) | RAB9AKDM4EMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL30831358 | 0.88 | RAB9A (0.70) | RAB9AKDM4EMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL2491850 | 0.86 | MAPT (0.70) | RAB9AKDM4EMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL7258748 | 0.86 | RAB9A (0.67) | RAB9AKDM4EMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL14699734 | 0.84 | KDM4E (0.68) | RAB9AKDM4EMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL2035125 | 0.81 | RAB9A (1.00) | RAB9AKDM4EMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL474369 | 0.80 | RAB9A (0.82) | RAB9AKDM4EMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL31154077 | 0.80 | RAB9A (0.82) | RAB9AKDM4EMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL14148310 | 0.80 | RAB9A (0.73) | RAB9AKDM4EMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL28579942 | 0.80 | RAB9A (0.86) | RAB9AKDM4EMAPTSMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090258917-A1 | Benzoxazoles Useful in the Treatment of Inflammation | BIOLIPOX AB (SE) | 2009-10-15 | — | — | US | disclosed |
| EP-1933834-A1 | BENZOXAZOLES USEFUL IN THE TREATMENT OF INFLAMMATION | Biolipox AB (SE) | 2008-06-25 | — | — | EP | disclosed |
| WO-2007042816-A1 | BENZOXAZOLES USEFUL IN THE TREATMENT OF INFLAMMATION | BIOLIPOX AB (SE) | 2007-04-19 | — | — | WO | disclosed |
| WO-2002036580-A9 | BENZOXAZOLE LPAAT- BETA INHIBITORS AND USES THEREOF | BONHAM LYNN (US) | 2003-02-13 | — | — | WO | disclosed |
| US-20020107269-A1 | Benzoxazole LPAAT-B inhibitors and uses thereof | CELL THERAPEUTICS, INC. | 2002-08-08 | — | — | US | disclosed |
| WO-2002036580-A2 | BENZOXAZOLE LPAAT- BETA INHIBITORS AND USES THEREOF | BONHAM LYNN (US) | 2002-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020107269-A1 | Benzoxazole LPAAT-B inhibitors and uses thereof | LPCAT3, LPCAT1, PLAAT2 | RAB9A 3729/4885KDM4E 1501/4885MAPT 4105/4885 |
| US-20090258917-A1 | Benzoxazoles Useful in the Treatment of Inflammation | IL4I1, EPX, IL4 | RAB9A 3680/4885KDM4E 1264/4885MAPT 270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.